Did a Permissive Scientific Culture Encourage the ‘CRISPR babies’ experiment?
By Donna Dickenson, Marcy Darnovsky,
Nature Biotechnology
| 03. 15. 2019
To the Editor — The claim last November by He Jiankui to have engineered the first CRISPR-edited babies has ignited voluble condemnation from scientists worldwide. What, then, made this rogue researcher think that his ‘achievement’ would be welcomed? One possible factor is that He claimed that he was influenced by the words and actions of key US and UK scientists. He attended and was an invited speaker at several meetings about gene editing, including several focused on the ethical acceptability of human germline modification1. And he explicitly cited the 2017 US National Academies of Science report as support for what he did2.
The Nuffield Council on Bioethics in the UK also issued a report in July 20183. Notably, it concludes that germline genome editing could be permissible under certain circumstances. More strongly, it moves beyond the merely permissible to the ethically obligatory, saying in its final section (paragraph 5.2) that “there are moral reasons to continue with the present lines of research and to secure the conditions under which heritable genome editing would be...
Related Articles
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...
By Claire Robinson and Jonathan Matthews, Guest Contributors
| 08.25.2026
This is an excerpt of an article originally published on August 1, 2026 at GMWatch.
A six-year-old girl has died in a gene editing gene therapy trial in China that went wrong, the journal Science reports. Seven days after the girl's medical team infused trillions of viruses carrying the recipe for the gene editing tool – in this case a base editor – into her spinal fluid, she died of a severe immune reaction linked to the therapy.
Just...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Sophie Ryall , BioNews | 08.03.2026
A fertility doctor is being sued for using his own sperm during artificial insemination procedures without the patient's knowledge or consent.
Dr Dennis Lutz used his own sperm repeatedly when treating patient Jean Ann Nelson at the Medical Arts Clinic...